Geron reports Q1 revenue growth and updates on blood cancer drug progress.

Geron Corporation reported better-than-expected Q1 earnings with revenue of $51.84 million, up nearly 31% year-over-year. The company is focused on treating blood cancers, particularly lower-risk myelodysplastic syndromes (MDS), with its telomerase inhibitor drug, imetelstat (RYTELO), which has been commercially available for about 18 months. Geron is also preparing for a mid-year data readout on imetelstat's potential in treating myelofibrosis, signaling ongoing development and growth prospects in hematological diseases.